EB Development said on 17 September it will file a public withdrawal offer and squeeze-out for the remaining shares in Eurobio Scientific at €25.30 each. It already controls just over 90% of the French diagnostics company.
Market context
The price mirrors EB Development's 2024 voluntary tender, which fell short of the squeeze-out threshold. Analysts put the implied valuation of the whole company at about €255m.
